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ABSTRACT
The Chinese Antibody Society (CAS) convened the second annual conference in Cambridge, MA, USA on
29 April 2018. More than 600 members from around the world attended the meeting. Invited speakers
discussed the latest advancements in therapeutic antibodies with an emphasis on the progress made in
China. The meeting covered a vast variety of topics including the current status of therapeutic antibodies,
the progress of immuno-oncology, and biosimilars in China. The conference presentations also included
the development of several novel antibodies such as antibodies related to weight loss, T-cell receptor-
mimicking antibodies that target intracellular antigens, and tumor-targeting antibodies that utilize both innate
and adaptive immune pathways. At the meeting, the CAS announced the launch of its official journal—
Antibody Therapeutics—in collaboration with Oxford University Press. The conference was concluded by
a panel discussion on how to bring a therapeutic drug developed in China to the USA for clinical trials.
Statement of Significance: The CAS convened the second annual conference in Cambridge, MA, USA on
29 April 2018. The meeting covered a variety of topics, including therapeutic antibodies being tested
in clinical trials, new antibodies (e.g., programmed cell death protein 1/programmed death-ligand 1
inhibitors) being developed in China, and T-cell receptor-mimicking antibodies that target intracellular
antigens.
KEYWORDS: antibody therapeutics; biosimilars; bispecific antibodies; CAR T cells; Chinese Antibody
Society
OPENING REMARKS
The second annual conference organized by the Chinese
Antibody Society (CAS) was held on 29 April 2018 in
Cambridge, MA. Dr Fubao Wang, the associate vice presi-
dent (VP) of Sanofi, the chair of the conference organizing
committee, and the board director of CAS, delivered the
opening remarks. He welcomed all attendees of the confer-
ence and thanked the speakers, panelists, and session chairs,
the conference organizing committee, and CAS volunteers
(Fig. 1), and partners and sponsors of the conference.
Wang mentioned that it is the golden age for antibody
therapeutics since the number of monoclonal antibodies
(mAbs) approved by the Food and Drug Administration
(FDA) has increased in recent years. As of 2017, the total
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Figure 1. A group portrait of the conference speakers, panelists, CAS advisors and volunteers taken during the second annual conference.
is 74 and 7, respectively. In particular, the FDA recently
approved Trogarzo, which is the first mAbmanufactured in
China. Additionally, 13 therapeutic antibodies that were
developed in China have received Investigational New
Drug (IND) clearance from the US FDA. There are also
many significant licensing deals linked to drug companies
in the USA and China. Wang highlighted the theme of
the conference—Antibody Therapeutics: Frontiers and
Opportunities—with an agenda that covered all major
aspects related to antibody therapeutics: science, technol-
ogy, clinical, regulatory, business, and intellectual property.
He welcomed the attendees to enjoy the event, to network
with fellow attendees, and to fully immerse in the full-day
activities.
MORNING SESSION
Yearly review and announcements of the CAS
Dr Shouye Wang, the director of WuXi Biologics and
the president of CAS, shared the milestone achievements
and the progress of CAS with the audience. Founded on
27 April 2016, CAS is the only global organization for
Chinese professionals whose work focuses on therapeu-
tic antibodies. It is a rapidly growing society with 1200+
members worldwide and 10 000+ WeChat followers. It is
a non-profit society that is operated fully by volunteers.
The mission of CAS is to serve as the gateway to the
globalization of therapeutic antibodies developed inChina,
and the platform is to foster the productive collaboration
and networking among its members. The current focus of
CAS is the “1111” plan that is to launch one journal—
Antibody Therapeutics—in collaboration with Oxford Uni-
versity Press (launched June 2018) and to organize a series
of one monthly webinar, one biannual PharmaConnect
function, and one annual conference.Wang announced that
the third annual conference will be held on 7 April 2019 in
Cambridge, MA. Another key announcement that Wang
made is thatDrZhidanTu is the president-elect of theCAS;
Tu is the director of Legend Biotech; and is currently the
general manager and VP of CAS.
Current status of therapeutic antibodies—2018
Following Wang’s introduction of the CAS, the next
presentation was delivered by Dr William Strohl, founder
of BiStro Biotech Consulting LLC and the former VP of
BioTherapeutics at Janssen. Strohl discussed the current
status of therapeutic antibodies approved by the FDA
for marketing and for use at the clinical stages. There has
been a large increase in FDA-approved antibodies in the
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(Fig. 2A). Antibodies drive the value of all biologics since
their sales accounted for 66% of biologics revenues in 2017
[1]. Until now, there are 84 FDA-approved antibody-based
drugs, including two chimeric antigen receptor (CAR)-T
therapies approved in 2017 (Fig. 2A). In addition, there
are about 800 antibody-based drugs that are undergoing
clinical development with close to 600 antibodies in
various formats with naked immunoglobulin G being
predominant (BiStro Biotech Database1). The remaining
200 are CAR antibodies loaded onto T and natural
killer (NK) cells. Many CAR-Ts are currently developed
in major universities and pharmaceutical companies in
China. Approaches to cancer antibody therapy include
blocking receptor and ligand interaction, interfering
with the tumor support, inducing tumor cell death,
delivering toxic payloads, activating the immune system
with checkpoint modulators, and targeting tumor cells
with the immune system such as complement-dependent
cytotoxicity and antibody-dependent cell-mediated cyto-
toxicity (ADCC). The therapeutic areas targeted by clinical
candidate antibodies and CARs are mainly oncology and
immunology, followed by infectious diseases, neurobiology,
and cardiovascular diseases (Fig. 2B). This correlates well
with the fact that a vast majority of targets are identified
in oncology, inflammation, and autoimmune diseases
(Fig. 2B). Cluster of differentiation (CD) 19, a B-cell
specific surface antigen that is often overexpressed in many
leukemia and lymphomas, is by now the largest targeting
pool, especially in the CAR-T field (Fig. 2B).
In the second part of his talk, Strohl focused on
antibodies and T cells. He first discussed the development
of checkpoint inhibitor or agonist antibodies to improve
T-cell activity. Over 100 checkpoint inhibitor antibodies
are currently in clinical trials. Several have reached
Phase III, and three are from companies in China. He
mentioned that one emerging question in the field is why
T-cell immunomodulators are working in some patients
but not others. Strohl next discussed the development of
bispecific antibodies for T-cell redirection. The orientation
of the CD3 arm that targets T cells is critical for potency.
There is also an interesting correlation of size and potency.
The smaller they are, the more potent they are [2]. One
hypothesis is that small molecules may lead to efficient
synapse formation between T cells and tumors, and the
number of interactions in synapse seems to be critical
with an optimal number of around 10 to 15. However, one
should bear in mind that smaller molecules have a shorter
half-life [3]. The third approach is CAR-T antibody-based
cell therapy. Strohl gave a brief overview of four generations
of CARs and described the differences between autologous
and allogeneic CAR-T designs [4]. The autologous CAR-T
is an individualized and patient-specific therapy because
it engineers T cells directly isolated from the patient. On
the contrary, the allogeneic CAR-T, which is also known
as the off-the-shelf therapy, is to engineer primary T/NK
cells isolated from healthy donors. This type of CAR-T
is to reduce the expensive cost arising from individualized
1 From BiStro Biotech Consulting database on clinical stage biologics.
Database lock for these data was 25 April 2018.
autologous therapy. There are four sources of allogeneic
cells [3, 5, 6]. One can directly engineer primary T/NK
cells or use T cells differentiated from induced pluripotent
stem cells. Alternatively, one could genetically engineer
an established cell line or use cord blood cells that nat-
urally lack major histocompatibility complexes (MHCs).
However, both autologous and allogeneic CAR-Ts have the
potential problems of delivering heterogeneous T cells and
uncontrolled T-cell expansion. Strohl concluded by saying
that only when we can achieve delivery of homogenous
cell types, will we be able to effectively treat tumors with
T cells.
Progress and status of Immuno-Oncology in China
In this talk, Dr Michael Yu, the president and CEO of
Innovent Biologics, summarized the progress and status
of immuno-oncology (IO) in China. As stated in his
introduction, many IO investigative drugs were filed in
China either for clinical trials or for marketing. The star
candidates are programmed cell death protein 1 (PD-1)/
programmed death-ligand 1 (PD-L1) inhibitors. Twenty-
nine PD-1/PD-L1 inhibitors were filed for INDs in China
as of 29 April 2018; 23 from domestic companies and 6
from multi-national companies. In terms of progress, 18
out of 29 are at clinical stage (11 for PD-1 and 7 for PD-L1)
including 5 biologics license applications (BLAs) filed
with China National Drug Administration (CNDA). IO
programs against other popular targets such as cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4), OX-40,
lymphocyte-activation gene 3, T-cell immunoglobulin and
mucin-domain containing-3, CD47, and PD-1/CTLA-4
bispecific are also being carried out in China.
In addition to the above-mentioned antibody programs,
Yu also introduced the flourishing INDs of engineered
T-cell therapy in China. The US FDA has approved one
dendritic cell therapy (Sipuleucel-T, Provenge) and two
CAR-T products [7, 8]. China has 15 CAR-T filed for IND
as of 29 April 2018.Most of the 15 CAR-T targeting CD19
and one CAR-T targeting BCMA from Nanjing Legend
were approved for Phase I clinical trial. There are 153CAR-
T clinical trials from China registered in ClinicalTrials.gov.
As a comparison, 155 US CAR-T clinical trials are regis-
tered. Statistically, China and the USA play leading roles
in CAR-T clinical trials (accounting for >70% of clinical
trials in the world).
In the second part of his talk, Yu reported on the current
progress of Innovent, which has a diversified pipeline with
four advanced products (in Phase III trials) and other
innovative I/O therapies. IBI308 mAb (sintilimab) is a
fully human anti-PD-1 antibody currently under Phase
II/III trials for Hodgkin lymphoma, esophageal cancer,
NK/T lymphoma, squamous non-small cell lung cancer
(NSCLC), and NSCLC. As shown in the crystal structures,
IBI308 binds to a different epitope from Pembrolizumab
and Nivolumab, which are the first two FDA-approved
mAbs targeting PD-1 (Fig. 3). IBI308 also shows 10-
and 50-fold higher affinity to human PD-1 expressed on
the surface of Chinese hamster ovary cells than Pem-
brolizumab and Nivolumab, respectively. A collaborative
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Figure 2. Current status of approved therapeutic antibodies. (A) The total number of approved therapeutic antibodies and antibody-like molecules such
as Fc fusion proteins and CARs is 84 as of 25 April 2018. This number is increasing at a rate of around six per year. (B) There are 325 unique targets
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Figure 3. Crystal structure of the IBI308 (Sintilimab) Fab-PD-L1-PD-1
complex. The light (L) and heavy (H) chains of Sintilimab Fab are shown
in salmon and cyan, respectively. PD-L1 is in pink and PD-1 is in light
blue (surface representation). The structure suggests that IBI308 can
efficiently block PD-1/PD-L1 and PD-1/PD-L2 interactions (PD-L1 and
PL-L2 binding sites on PD-1 are mostly overlapped). In addition, the
binding epitope of IBI308 is distinct from that of Pembrolizumab and
Nivolumab.
a much stronger in vivo anti-tumor efficacy in humanized
NOD scid gamma mouse model where IBI308 at 1%
dose achieves better anti-tumor activity than Nivolumab.
In vitro functional assay shows that IBI308 stimulates
higher activation of T cells, which is further supported
by ex vivo assay in MC38 tumor-bearing mouse model
that shows IBI308 promotes higher effector: regulatory
T cell ratio than Pembrolizumab and Nivolumab. A very
recent report shows that IBI308 has a similar safety profile
to Pembrolizumab and Nivolumab in Phase II study for
Hodgkin lymphoma. A new drug application was filed
with CNDA in April 2018 and granted with priority review
status. Further results on the efficacy of IBI308 were
reported at the 2018 ASCO Annual Meeting in Chicago.
The trial result showed positive response in patients with a
74.0% objective response rate and 24.0% complete response
rate, making it a new treatment for relapsed/refractory
classical Hodgkin’s lymphoma patients [9].
Innovent IBI322, an anti-CD47/PD-L1 bispecific mAb,
is currently under pre-clinical study. CD47 is a well-
characterized cell surface receptor that conveys a “don’t
eat me” signal to immune cells [10]. However, the broad
expression of CD47 on normal cells limits its therapeutic
potential. IBI322 has both anti-CD47 and anti-PD-L1
arms in which the affinity to PD-L1 is stronger than CD47.
This suggests that IBI322 has the potential to preferentially
bind to PD-L1 positive tumor cells over healthy cells.
This could lead to a superior toxicity profile. Preliminary
studies show that IBI322 selectively binds to PD-L1
positive tumor cells over red blood cells so that it does
not induce hemagglutination. Moreover, there is evidence
that IBI322 has more potent phagocytosis activity and
anti-tumor efficacy than individual anti-CD47 and anti-
PD-L1 controls whereas it retains a normal antibody-like
pharmacokinetics (PK) profile. In conclusion, preliminary
study results have shown great potential for IBI322 as a
novel therapeutic in the IO family.
Anti-GFRAL antibodies
Next, DrWenyan (David) Shen, the Senior VP of Biologics
Research, Bioanalytical and Chemistry, Manufacturing &
Control (CMC) at NGM Biopharmaceuticals, described
recent novel therapeutic development in NGM with a pri-
mary focus on GDF15, a soluble hormone that is related
to obesity. GDF15 is known as growth and differentiation
factor 15, and its administration lowers body weight and
reduces food intake in mice in a dose-dependent manner.
The recent identification of its cognate receptor, GDNF
Family Receptor Alpha Like (GFRAL), has shed light on
the mechanism of action of GDF15. GFRAL was identi-
fied by NGM via unbiased cell-based/biochemical screen-
ings approach [11]. Binding of GFRAL toGDF15 has been
demonstrated both in vitro using recombinant proteins with
a dissociation constant (KD) of 8 nM and in tissue culture
cells with a KD in low molar concentration (nM) [11].
GFRAL knockout mice are resistant to GDF15-induced
weight loss. Both GDF15 and GFRAL are therefore two
potential drug targets for diseases related toweight changes.
Despite the promising efficacy of GDF15, the recombi-
nant protein presents manufacturing challenges because
of its solubility issue at higher concentration. Mutational
analysis based on the co-crystal structure of GDF15 and
GFRAL [11] led to the generation of two highly potent
GDF15 variants that display significant solubility improve-
ment. Currently, these GDF15 agonists are under develop-
ment by Merck through licensing from NGM. In addition,
NGM also develops an anti-GFRAL antagonist antibody
that is currently under Phase I clinical trial. This anti-
body reverses GDF15-induced weight loss and promotes
weight gain in mice. It is intended to be used in cancer
patients to prevent or to minimize weight loss induced by
chemotherapy.
TCR-mimicking antibodies
The next talk from Dr Cheng Liu, founder and CEO of
Eureka Therapeutics, featured recent developments toward
intracellular cancer targets. The traditional therapy, such as
mAbs and CAR-Ts, recognizes extracellular or surface pro-
teins. However, the cancer targeting proteome comprises
nearly 90% of the intracellular targets [12]. MHC class
I complexes present peptides derived from intracellular
targets on the cell surface, and this makes them attrac-
tive targets. One example is Wilms Tumor (WT-1) peptide
presented by the MHC class I A0201 complex. WT-1 is
expressed broadly inmany types of cancer but rarely in nor-
mal adult tissues. The proprietary in-house phage display
platform for fully humanized antibodies allows Eureka to
develop a first-in-class monoclonal, fully human antibody
against WT-1 [13, 14]. The antibody mediates ADCC in
vitro and shows strong anti-tumor effects in vivo. It is
one of the first therapeutic antibodies that directly target
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Figure 4. A schematic diagram showing a TCR-mimicking monoclonal
antibody binding to a peptide/MHC complex on a cancer cell. Intracellu-
lar tumor-associated antigens (TAAs) are processed and presented on the
surface of malignant cells in the context of MHC class I molecules. Highly
specificTCR-mimicking mAbs can nowbe isolated and used to specifically
target malignant cells exhibiting specific TAA/MHC complexes on their
surface. TCR-mimicking antibodies can be used for CAR-T immunother-
apy as well as therapeutic mAbs.
Liu also shared another significant progress that the
company has made on the development of T-Cell Receptor
(TCR)-mimicking antibodies. Alpha-fetoprotein (AFP) is
a fetal protein highly and specifically expressed in liver
tissues, and its peptide is presented by the MHC class I
A0201 complex on the cell surface. To develop a TCR-
like antibody, they took a different approach, which was
to develop CAR-T that recognizes the MHC class I com-
plex presenting the AFP peptide (Fig. 4). A highly specific
single-chain variable fragment against the MHC complex
with the AFP peptide was isolated from a phage library
and was cloned into a CAR structure [15]. The resulting
AFP-CAR T cells selectively kill cancer cells that express
both MHC class I A0201 and AFP and triggers antigen-
dependent activation of antigen-positive tumor cells [16].
The intratumoral or intraperitoneal delivery of AFP-CAR
T cells causes robust tumor regression [16]. This is the first-
in-human TCR-mimicking antibody developed for liver
cancer and is currently undergoing Phase I clinical trial.
Development of biosimilars in China
Dr Scott Liu gave a comprehensive talk on the development
of biosimilars in China. He started with a discussion on
the medicine affordability issue in China where there is a
large population of cancer patients, most of whom cannot
afford the expensive mAb treatment. Although there is a
steady improvement on China’s healthcare, the ratio of
Trastuzumab’s price to the annual healthcare expense ratio
in China, for example, is still over 9-fold greater than in the
USA, resulting in a low human epidermal growth factor
receptor 2 (HER2)+-breast cancer treatment rate in China
(<10%) [17]. Treatment rates for other popular mAbs are
far from ideal in China as well: 18.9% for Rituxan, 0.02%
for Humira, 1.9% for Avastin, and 1.1% for Erbitux (IMS
data, 2017). This is primarily due to the affordability issue
of mAb treatment.
Liu also criticized the lack of availability of biologics in
China. During 2010–14, China’s patients only had access
to 6 newly approved cancer drugs from a total of 49 in
the world, whereas patients in the USA had access to 41
of them [18]. In contrast to the poor accessibility to mAb
treatment, China has a big cancer patient population. Lung
cancer patients, for example, accounted for 37% of the
world’s incidence and liver cancer accounted for 52% of
the world’s incidence in 2015 [19]. This indicates that there
are enormous unmet medical needs and a huge potential
biosimilar market in China as evidenced in the flourish-
ing trends in venture capital/private equity investment for
biotech companies in China. From the prospect of gov-
ernment policy, reforms of China healthcare regulations
have sped up since 2015. The new policies have encouraged
innovation and competition resulting in increased accessi-
bility and affordability of quality medicines to patients in
China. Moreover, CNDA issued a series of guidelines and
policies to speed up the development of innovates, generic
drugs, and biosimilars. These efforts have paved the way for
a booming age of biosimilars in China where the number
of mAb biosimilar IND submissions surged to a historical
peak in 2015. At present, clinical trials are highly central-
ized on the biosimilars of the top five hot targets on the
market (bevacizumab, adalimumab, rituximab, cetuximab,
and trastuzumab). Among them, there are 24 biosimilars
under Phase I clinical trials, 23 in Phase II/III, and 43
just received IND approvals. Nearly each of the top five
mAbs (except for trastuzumab) has 10–30 players in China.
However, this market was once in chaos as most of the
early filings before 2012were not genuine biosimilars, which
should have the same amino acid sequences as the originals,
according to the biosimilar guidelines. Even today, the
number of “genuine biosimilars” in China remains low.
Only less than five true biosimilars for each popular mAb
originators are in clinical development. Liu concluded that
the limitation of R&D capability is the major hurdle for
more players to jump into this game.
Liu further expounded on Henlius’ leading position in
biosimilar development in China. In this highly compet-
itive market of biosimilars, where speed is the key, Hen-
lius’ first four biosimilar products (HLX01–HLX04) pio-
neer the competitive landscape in China. In 2018, HLX01
(Rituximab biosimilar) is expected to be approved for mar-
keting and, therefore, is likely to be the first genuine biosim-
ilar to be launched in China.
Liu then took HLX02 as a case study to elaborate the
successful development of biosimilars in China. HLX02
is an anti-HER2 trastuzumab biosimilar. Its proposed
action mode includes Trastuzumab-mediated ADCC
and inhibition of the mitogen-activated protein kinase
and Phosphatidylinositol-4,5-bisphosphate 3-kinase/alpha
serine/threonine-protein kinase pathways, which leads to
cell cycle arrest [20]. In the CMC perspective, the physical
and chemical properties, biological activity, purity, and
stability were assessed for HLX02. HLX02 has exactly the
same amino acid sequences as Genentech’s Herceptin as
assessed with peptide mapping, mass spectrometry, and N-
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biosimilar and originator were shown in circular dichroism
spectra, and similar charge heterogeneity was shown in
cation exchange chromatography. Highly similar glycan
profile, though slightly increased in salicylic acid content
for HLX02, was shown in comparison to trastuzumab.
Moreover, HLX02 has highly similar anti-proliferation,
ADCC activities, antigen binding, C1q binding, apoptosis
activities, and Fc receptor binding to trastuzumab.
In the non-clinical study of HLX02, it showed simi-
lar potency and inhibitory effect with Herceptin in tested
cyno monkey and mouse models. Toxicology with single-
and multiple-dosed study in cyno monkey shows no sig-
nificant change in physiological presentations. Thus, toxic
characteristics of HLX02 were highly similar to those of
Herceptin. In terms of clinical study, Phase I of HLX02
established the similarity in PK and safety profile compared
to Herceptin. Phase III study is currently ongoing globally,
which endorsedHLX02 as the first Trastuzumab biosimilar
produced by a Chinese biotech company advancing into
Phase III study in European Union (EU) regions.
Finally, Liu described that HLX04 (a bevacizumab
biosimilar) has completed a randomized, double blind,
parallel group and four-arm comparison Phase I trial in
208 healthy male participants over a period of 120 days.
AUC (0-∞) and Cmax data between HLX04 group and
three control groups (CN-source Avastin, US-source
Avastin, and EU-source Avastin) are all highly similar.
This demonstrates PK bioequivalence between HLX04
and Bevacizumab. HLX04 is currently under Phase III for
metastatic colorectal cancer (the first of its kind in China).
AFTERNOON SESSION
Tumor-targeting antibodies
Dr Yang-Xin Fu from the Department of Pathology and
Immunology at UT Southwestern discussed how tumor-
targeting antibodies kill tumors. Using anti-HER2/neu
antibody and anti-CD20 as examples, he showed that
these antibodies control tumor regression in a T-cell and
interferon (IFN)-dependent manner [21, 22]. It is likely
that antibodies that block oncogenic receptors can trigger
innate sensing. This leads to an increased cross-priming of
T cells that is essential for tumor killing. He also discussed
the mechanisms of anti-CD47 antibodies. Tumor cells that
highly express CD47, which presents a “do not eat me” sig-
nal, are often more resistant to conventional treatment [23].
It is thought that anti-CD47 antibody that blocks signal-
regulatory protein signaling by CD47 regresses tumors via
macrophage-mediated phagocytosis. Interestingly, studies
from Fu’s group show that the therapeutic effect of anti-
CD47 depends on type I IFN and that the STING pathway
is essential for type I IFN production [24]. Dendritic cells,
but not macrophages, respond to IFN for cross-priming
mediated by anti-CD47 antibody [25]. Fu’s studies suggest
that tumor-targeting antibodies involve both innate and
adaptive immune responses to control tumor killing [26].
Fu ended his presentation by raising an interesting point on
the potential use of type I IFN. His group fused IFN with
antibody in various ways. Current studies show that IFN
antibody fusion proteins are able to induce CD8-dependent
T-cell responses through an increased cross-priming [27].
Fu termed them next-generation antibodies and proposed
that they are able to bring more IFN to tumor tissues to
enhance immune responses and to help kill tumors that
become antibody resistant.
Launch of Antibody Therapeutics, a new open access
journal
Dr Mitchell Ho, from the US National Cancer Institute
(NCI), is the founding Editor-in-Chief of Antibody Thera-
peutics, the official journal of CAS.Ho started by reviewing
the progression of the launch of the new peer-reviewed
journal. After more than 1 year of preparation, Oxford
University Press was selected as its publisher, and the first
issue was scheduled to be released from June to August.
Unlike traditional journals that publish all of the papers
of an issue at one time, Antibody Therapeutics, as an open
access journal, will publish papers as they are accepted.
Ho stated that the scope of this new journal is to serve
as a forum to report the latest advances and challenges in
the discovery, research, development, manufacturing, and
methodology of therapeutic antibodies for the global sci-
entific community as well as members of CAS. Its contents
will include original research, reviews, methods, regulations
and policies, news, interviews, and meeting highlights. Ho
also introduced the editors and editorial board members
of the journal and called for manuscript submissions. Ho’s
inaugural editorial appeared on 20 June 2018 [28].
In his talk,Hooverviewed the history of therapeutic anti-
body discovery and engineering. He believes that a major
challenge in the field of antibody therapeutics is to develop
effective therapies for solid tumors that are killing most
cancer patients worldwide. For solid tumors we know little
about what tumor antigens can be safely and effectively
targeted to discriminate cancers from normal tissues. He
then discussed what are potentially good tumor antigens
in four categories: first, antigens are expressed on cancers
and on non-essential normal tissues including mesothelin
[29, 30] and glypican-3 [31, 32], two examples that his
laboratory research has focused on for many years; second,
shared antigens/mutations are unique to cancer (e.g.,
epidermal growth factor receptor variant III, KRAS
mutations) [33, 34]; third, mutations/variants unique to
each individual (e.g., patient-specific neoantigens) [35];
and fourth, protein conformations, splice variants, or
glycosylations and other post-translational modifications
unique to cancer. Near the end of his talk, Ho described
the single-domain antibodies developed by his laboratory
that are capable of reaching buried functional sites in
tumor antigens and inhibiting cancer signaling [36–38].
Ho believes that single-domain antibodies that are easy
to express and bind buried functional sites of the protein
complexes that are involved in tumor progression are worth
pursuing as a new class of cancer therapeutics.
Challenges in the clinical development of antibody-drug
conjugates
In the next talk, Dr Yong-jiang Hei gave an introduction
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Even though there have been a few ADCs approved and
marketed in the USA, notable examples of which are
Brentuximab vedotin (Adcetris), Trastuzumab-emtansine
(T-DM1) (Kadcyla), Inotuzumab ozogamicin (Besponsa),
and Gemtuzumab ozogamicin (Mylotarg), the failure rate
of clinical trials remains high for ADCs (most stopped in
Phase I or II). First, Hei introduced Trastuzumab-MCC-
DM1 (T-DM1), which is composed of an anti-HER2
Trastuzumab, anti-mitotic toxin payload (DM1), and a
stable and non-reducible thioether-linkage [39]. T-DM1
was approved based on the EMELIA trial, which showed
improved progression-free survival (PFS) as well as overall
survival (OS) versus lapatinib plus capecitabine in the
second-line treatment of Her2-positive metastatic breast
cancer (MBC). However, T-DM1 later suffered failures in
the first-lineMBC (MARIANNE trial). T-DM1 or T-DM1
plus pertuzumab failed to show an improvement in PFS
when compared to trastuzumab plus taxane chemotherapy,
which was the standard of care in the first-line treatment
of MBC at the time the trial was conducted. In another
Phase III trial known as GATSBY, T-DM1 was compared
to chemotherapy in the second-line treatment of advanced
gastric cancer and showed no difference in OS. In addition,
the KRISTINE trial tested T-DM1 in early breast cancer
in the neoadjuvant setting whereas the data show the
pathological complete response rate was not improved
when compared to the control group. There are two
ongoing clinical trials on T-DM1: Kaitlin and Kathrine,
the results of which are much anticipated.
Another ADC that Hei introduced is Brentuximab
Vedotin (Adcetris). This ADC shows a high objective
response rate in Phase II pivotal trial for Hodgkin’s
lymphoma patient population and PFS benefit in a
Phase III study (ECHELON-1 study). In another study
(AETHERA), brentuximab vedotin was used as consol-
idation therapy after autologous stem-cell therapy for
Hodgkin’s lymphoma patients and showed improved PFS,
but the result showed no difference in OS. This is likely due
to the crossover that means patients in both arms receive
the investigational agent but patients in the control arm
receive it at a later time point.
Hei also commented on newly approved ADCs: (1) Ino-
tuzumab Ozogamicin showed improved rate of complete
remission compared to the standard therapy for acute lym-
phoblastic leukemia. Improvement of PFS and OS were
also observed. (2) Gemtuzumab ozogamicin (Mylotary),
which was re-approved based on cumulative evidence and
an investigator-initiated trial, after it was withdrawn from
the US market in 2010. Hei remarked that a few lessons
we could learn from ADC clinical trials are that people
could make smart clinical design to improve probability of
trial success, for example, a good management of toxicity
in early phase trials, and careful patient selection.
Hei then shared his insights into the molecular design of
ADCs that could improve their performance. He stressed
the expertise on linker chemistry that could minimize pay-
load release prior to reaching tumor cells. This in turn
increases stability and half-life of ADCs and its chances of
internalization. Payload is another key element. It should
maximize tumor-killing efficacy while avoiding cross resis-
tance and toxicity toward normal cells. Current clinical
evidence indicates how integration of these attributes is
critical to the success of the molecule.
Finally, Hei listed a few ADCs to watch in 2018: (1)
IMMU-132, the BLA of which was submitted in May
2018, with potential approval for marketing in Q4 2018;
(2) Rova T (originally developed by Stemcentrx and pur-
chased by AbbVie); poor Phase II data blocked its accel-
erated approval; (3) DS-8201a, which has an outstanding
linker stability and high cytotoxic agent potency; (4) nectin-
4 ADC (enfortumab vedotin), which is under Phase I/II
clinical trial and was granted breakthrough therapy des-
ignation; and (5) epithelial cell adhesion molecule-ADC,
ongoing Phase III trial in bladder cancer.
Bio-innovation & global IP strategy—practical insights
Dr Teresa Lavoie from Fish & Richardson gave a talk
on intellectual property (IP) strategy for bio-innovations
and strategies for global patent filing. First, she shared a
few examples of patent portfolios related to therapeutic
antibodies of big biopharmaceutical companies. She then
pointed out that this is a very competitive market. There
have been reports on the $625 million settlement between
Merck and Bristol-Mayer Squibb to resolve the PD-1 anti-
body patent litigation. For the IP strategy, she also used
Humira, the best-selling mAb in the world, as an example.
Though the patent for the composition expired in 2016,
Humira is still well protected by a huge patent portfolio.
For example, the indications, methods of treatment, for-
mulations, and manufacturing methods, among others, are
still under patent protection. Clearly, it is very expensive
to build a huge portfolio around a biopharmaceutical, but
it can be worth it if it can effectively protect the product
by keeping competitors and biosimilar products off the
market.
Lavoie further commented on recent changes of the US
patent law that are significant for patenting in the bio-
pharmaceutical field. Based on this, she gave a few sugges-
tions on portfolio strategy from the perspective of a patent
lawyer: (1) for products that bind to first-in-class targets,
avoid premature filing of applications that do not include
significant description of the product, as such an approach
might reduce the ability to obtain a broad claim—aim
to include significant description of exemplary antibodies,
preferably described both by sequence and by functional
parameters; and (2) for best-in-class products, focus on
sequence and functional features, demonstrate an unex-
pected advantage over existing products (including, for
example, new or improved biological activity, significant
improvement in affinity, lower immunogenicity, better PK
properties, better expression level, and better stability in
solution). These unexpected advantages are necessary for
overcoming the obviousness rejection in certain jurisdic-
tions (e.g., in Europe).
PANEL DISCUSSION
During the past few years, more and more Chinese phar-
maceutical companies have submitted or are in the process
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USA. Filing an IND application is the first step in obtain-
ing permission from the FDA to conduct clinical trials in
the USA. As of 11 May 2018 at least 14 US INDs have
been filed for therapeutic antibodies (including ADCs and
single-domain antibodies) that were developed in China.
In the panel discussion, the four panelists—Dr Daotian
Fu, General Manager from Livzon MabPharm; Dr Scott
Liu, CEO from Henlius Biopharmaceuticals; Dr Weikang
Tao, CEO fromHengrui R&DCenter; and DrWendy Yan,
SVP from BeiGene—shared their experiences and insights
regarding successful filing of INDs with the US FDA.
According to the panelists, manymajor Chinese biophar-
maceutical companies choose to file IND applications in
the USA as part of their global strategy. These Chinese
biopharmaceutical companies have demonstrated strong
interest in making inroads into the US market as a testa-
ment of their ability to win the endorsements and approvals
by the US FDA and indeed have the ambition to use the
USA as the first stepping stone to become a major player
in this global drug market.
The US FDA applies the same regulatory and scientific
standards to all regulatory applications submitted by
sponsors, including Chinese companies. Many Chinese
companies typically work through their US subsidiaries
or contract agents based in the USA to directly interact
with the FDA for their IND filings.
China recently joined the International Council for
Harmonisation of Technical Requirements for Pharmaceu-
ticals for Human Use in pursuant of global harmonization
of drug development standards and adopted a new
guideline for clinical trials. The new guideline has made
filing of IND applications in both the USA and in China at
the same time much easier. However, difference in filing of
INDs with CNDA and FDA still exists. Thus, if a company
plans to submit an IND in the USA and in China at the
same time, the company should plan in advance and be
more strategic about the filing process.
In order to obtain the FDA’s approval, many Chinese
biopharmaceutical companies take advantage of a pre-
IND meeting with the FDA. A pre-IND meeting gives the
sponsor company the opportunity to introduce their prod-
uct to the FDA and gain the FDA’s concurrence with their
clinical development plan. In order to ensure the success
of the pre-IND meeting, the pharmaceutical company is
expected to provide a solid package with all data collected
to date (including data from pre-clinical animal studies).
Entering the US market is a long and complicated
process. Aside from regulatory requirements, IP protec-
tion is also very important. There is a fair degree of
uncertainty regarding how Chinese biopharmaceutical
companies could address potential patent infringement
issues (e.g., various PD-1 patents). While many Chinese
pharmaceutical companies currently focus on advancing
their molecules in clinical development in order to win
the FDA’s approval for marketing, a clear path forward is
still needed to address these potential IP issues. Chinese
biopharmaceutical companies should work more closely
with reputable IP law firms in the USA that have experience
in patent filing and can provide advice on US IP issues.
In summary, successful filing of an INDwith the FDA is
a critical step to move a product to the next stage of clinical
development, and is one of the most important milestones
on the protracted drug development process that leads to
final approval, which on average can take around 12 years.
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